Quince Therapeutics (fka Cortexyme) Files 8-K
Ticker: QNCX · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-info, name-change
Related Tickers: QUIN
TL;DR
Quince Therapeutics, formerly Cortexyme, filed an 8-K confirming its HQ address and corporate history.
AI Summary
On October 17, 2025, Quince Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080. The company's former name was Cortexyme, Inc., with a name change effective January 4, 2016.
Why It Matters
This filing confirms the current operational details and corporate history of Quince Therapeutics, Inc., including its former identity as Cortexyme, Inc.
Risk Assessment
Risk Level: low — This is a routine filing confirming corporate information and does not indicate any new material events or risks.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- Cortexyme, Inc. (company) — Former company name
- October 17, 2025 (date) — Date of Report
- 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080 (address) — Principal executive offices
- January 4, 2016 (date) — Date of name change
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Quince Therapeutics, Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported is October 17, 2025.
What is the company's former name?
The company's former name was Cortexyme, Inc.
When was the company's name changed from Cortexyme, Inc.?
The date of the name change was January 4, 2016.
Where are Quince Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-10-17 16:11:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX The Nasdaq Stock Mar
Filing Documents
- d75404d8k.htm (8-K) — 24KB
- 0001193125-25-242514.txt ( ) — 136KB
- qncx-20251017.xsd (EX-101.SCH) — 3KB
- qncx-20251017_lab.xml (EX-101.LAB) — 18KB
- qncx-20251017_pre.xml (EX-101.PRE) — 11KB
- d75404d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUINCE THERAPEUTICS, INC. Date: October 17, 2025 By: /s/ Dirk Thye Name: Dirk Thye Title: Chief Executive Officer and Chief Medical Officer